• 个人简介

• 科研领域

• 代表性论文

• 实验室简介

个人简介

个人介绍

王茜博士长期从事与病毒感染及保护性免疫应答机制相关的研究，在病毒进化与免疫逃逸、免疫原设计、疫苗效价评估、抗体分离等方面取得了有影响力的科研成果。发表论文40余篇，包括Nature、Cell、NEJM、Lancet、Cell Host Microbe、Lancet ID、Cell Reports等，论文他引4900多次。

教育经历

2009.09 至 2013.07 北京林业大学，本科
2013.09 至 2019.01 清华大学，博士

工作经历

2016.10-2017.04 洛克菲勒大学，访问学者

2019.09-2022.03 哈佛医学院，博士后

2020.04-2020.06 哥伦比亚大学，访问学者

2022.04-2024.04 哥伦比亚大学，副研究员

2024.05-2025.04 哥伦比亚大学，助理教授

2025.05-今 武汉大学，教授

荣誉奖励

2023年，国家自然科学基金优秀青年科学基金项目（海外）

2023年，中国区“35岁以下科技创新35人”

2023年，湖北省百人计划

社会服务

Nature Medicine, The Lancet Infectious Diseases, Cell Host & Microbe, Cell Reports, Cell Reports Medicine, eBiomedicine, Emerging Microbes & Infections, Frontiers of Medicine, Virus Research等杂志审稿人

Pathogens, Vaccines特邀编辑

执教课程

人类病毒学

武汉大学硕博研究生课程

科研领域

王茜博士长期从事病毒进化、感染机制及人体体液免疫应答等相关研究。未来将重点围绕病毒变异传播的分子基础、免疫压力驱动下的抗原变异机制、病毒进化路径预测、以及群体免疫监测等方向开展工作，旨在揭示病毒长期演化与公共健康风险之间的内在联系。

代表性论文

1. Wang Q*, Guo Y*, Casner RG*, Yu J, Nair MS, Ho J, Reddem ER, Tzang CC, Huang Y, Shapiro L, Liu L. Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2. Nature Communications 2025. Accepted.

2. Wang Q*, Guo Y*, Ho J, Ho DD. Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages. New England Journal of Medicine 2024 Nov 14;391(19):1863-1864.

3. Wang Q*, Guo Y*, Mellis IA*, Wu M*, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Reports. 2025 Apr 8;44(4):115543. doi: 10.1016/j.celrep.2025.115543.

4. Wang Q*, Mellis IA*, Wu M*, Bowen A*, Gherasim C, Valdez R, Shah JG, Purpura LJ, Yin MT, Gordon A, Guo Y, Ho DD. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. The Lancet Infectious Diseases 2025 Feb 4:S1473-3099(25)00058-1.                                              

5. Wang Q*, Mellis IA*, Ho J*, Bowen A, Kowalski-Dobson T, Valdez R, Katsamba PS, Wu M, Lee C, Shapiro L, Gordon A, Guo Y, Ho DD, Liu L. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerging Microbes & Infections 2024 Sep 11:2402880.

6. Wang Q*, Mellis IA*, Guo Y*, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster. Cell Reports Medicine 2024 Aug 23:101701.

7. Wang Q*, Guo Y*, Bowen A*, Mellis IA*, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. Cell Host & Microbe 2024 Mar 13;32(3):315-321.e3.

8. Wang Q*, Guo Y*, Schwanz LT*, Mellis IA*, Sun Y, Qu Y, Urtecho G, Valdez R, Stoneman E, Gordon A, Wang HH, Ho DD, Liu L. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Emerging Microbes & Infections 2024 Dec;13(1):2359004.

9. Wang Q, Zhang S, Nguyen HT, Sodroski JG. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells. Journal of Virology 2024 Feb 20;98(2):e0159423.

10. Wang Q*, Guo Y*, Liu L*, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L, Ho DD. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 2023 Dec;624(7992):639-644.

11. Wang Q*, Guo Y*, Tam AR*, Valdez R, Gordon A, Liu L, Ho DD. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Reports Medicine 2023 Nov 21;4(11):101258.

12. Wang Q*, Bowen A*, Ho J*, Zhang RM*, Valdez R, Stoneman E, Gordon A, Liu L, Ho DD. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet 2023 Nov 18;402(10415):1827-1828.

13. Wang Q*, Guo Y*, Zhang RM*, Ho J*, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L, Ho DD. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The Lancet Infectious Diseases 2023 Oct;23(10):e397-e398.

14. Wang Q*, Li Z*, Guo Y*, Mellis IA*, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L, Ho DD. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 2023 Oct 18;26(11):108254.

实验室简介